Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Autoimmune and Hematological Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CLEC4C/CD303 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CLEC4C ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View CLEC4C Products |
| Gene Delivery | CLEC4C Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View CLEC4C Products |
| Benchmark Ab | Anti-CLEC4C (Sequence of Litifilimab) Recombinant positive control. |
View CLEC4C Products |
| Validator | CLEC4C siRNA Set For knockdown verification. |
View CLEC4C Products |
| Related Target A | TLR7 Synergistic pathway in pDC activation and interferon production. |
View TLR7 Products |
| Related Target B | CD123 Co-targeted marker for pDC-driven malignancies and leukemias. |
View CD123 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Evaluating Rapid Internalization Dynamics | Human/Cyno ortholog ECD-Fc proteins available with >95% purity for internalization assays. |
| Conformation-Specific Binding | HEK293 Expressed (Native Glycosylation) proteins ensuring accurate structural epitopes. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live CLEC4C/CD303 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CLEC4C/CD303 therapeutics is intensifying, with major players shifting focus from traditional mAbs to targeted degraders and ADCs for pDC-driven diseases. As first-generation therapies for Systemic Lupus Erythematosus (SLE) reach advanced clinical stages, the next wave of R&D is targeting bispecific modalities to selectively modulate interferon pathways without broad immunosuppression.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody | Biogen, AstraZeneca | SLE, Cutaneous Lupus | Receptor Internalization Assay (Need high-purity ECD-Fc) |
| ADC | Emerging Biotechs | BPDCN, pDC Leukemias | Payload Delivery Validation (Need Lentivirus for Stable Cell Lines) |
| Bispecific | Various | Autoimmune Diseases | Heterodimer Validation (Need Cross-reactive Abs) |